Management of Thrombocytopenia in Robotic Mitral Valve Replacement with Bioprosthetic Valve

Anticoagulation Strategy

• The American College of Cardiology recommends initiating warfarin anticoagulation targeting INR 2.5 (range 2.0-3.0) for at least 3 months, and preferably up to 6 months after bioprosthetic MVR, even with platelets of 89,000, as this level does not constitute a contraindication to anticoagulation in the context of high thrombotic risk 1, 2, 3.
• Bioprosthetic mitral valves carry higher thromboembolic risk than aortic valves (2.4% vs 1.9% per patient-year), making anticoagulation particularly important 4, 5.
• Anticoagulation reduces thromboembolism from 3.9% to 2.5% per year in bioprosthetic MVR patients 2, 3.

Bleeding Risk vs Thrombotic Risk Balance

• At platelet count of 89,000, proceed with warfarin anticoagulation as bleeding risk does not significantly increase until platelets fall below 50,000 in most patients 1, 2.
• The American College of Cardiology notes that the Danish registry demonstrated no significantly increased bleeding risk with warfarin in post-bioprosthetic valve patients, while showing clear reduction in stroke and death 6, 7, 2.

Alternative Antiplatelet Therapy

• If warfarin is absolutely contraindicated due to bleeding concerns, aspirin 75-100 mg daily is reasonable as second-line therapy, according to the American Heart Association 7, 8.
• However, aspirin alone provides inferior protection compared to warfarin for bioprosthetic MVR 7, 8.

Long-Term Management

• Discontinue warfarin after 3-6 months if patient remains in sinus rhythm with no other indication for anticoagulation (atrial fibrillation, left atrial enlargement, history of thromboembolism, hypercoagulable state), as recommended by the American College of Cardiology 1, 4, 5.
• Continue aspirin 75-100 mg daily indefinitely after stopping warfarin, as suggested by the American Heart Association 7, 8.